Apogee Therapeutics, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
APGE Nasdaq 2830 www.apogeetherapeutics.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Apogee Therapeutics, Inc.

This Apogee Therapeutics Insider Increased Their Holding In The Last Year - Dec 25th, 2024 11:33 am
Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG333, its Novel Half-Life Extended TSLP Antibody for the Treatment of Respiratory and Broader I&I Conditions - Dec 10th, 2024 12:00 pm
Apogee Therapeutics Advances in I&I Disease Treatments - Dec 3rd, 2024 11:52 am
Apogee Therapeutics Highlights Progress and Best-in-Class Potential of Novel Biologic Programs for I&I Diseases at 2024 Inaugural R&D Day - Dec 2nd, 2024 11:00 am
Apogee Therapeutics Announces Agenda for Virtual R&D Day - Nov 29th, 2024 6:00 pm
Apogee Therapeutics to Host Inaugural Virtual R&D Day on December 2, 2024 - Nov 18th, 2024 12:30 pm
Apogee Therapeutics (NASDAQ:APGE) Is In A Good Position To Deliver On Growth Plans - Nov 14th, 2024 12:22 pm
Apogee reports Q3 EPS, expects cash to fund operations into Q1 of 2028 - Nov 13th, 2024 12:21 pm
Apogee Therapeutics Provides Pipeline Progress and Reports Third Quarter 2024 Financial Results - Nov 12th, 2024 12:00 pm
Apogee Therapeutics to Participate in Upcoming November Investor Conferences - Nov 4th, 2024 12:30 pm
Apogee Therapeutics Announces Results Up to 9 Months from Phase 1 Trial of APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases - Oct 24th, 2024 12:00 pm
Apogee Therapeutics Announces Poster Presentation at the ACAAI 2024 Annual Scientific Meeting - Oct 16th, 2024 11:00 am
Apogee Therapeutics, Inc. (APGE): A Hot Stock to Buy Now - Oct 7th, 2024 8:50 pm
Wellington Management Group LLP Increases Stake in Apogee Therapeutics Inc - Oct 4th, 2024 5:03 pm
Apogee Therapeutics to Participate at the Stifel 2024 Immunology and Inflammation Summit - Sep 12th, 2024 11:00 am
Apogee Therapeutics Appoints Jeff S. Hartness as Chief Commercial Officer - Sep 9th, 2024 11:00 am
Insider Sale: Carl Dambkowski Sells Shares of Apogee Therapeutics Inc (APGE) - Sep 7th, 2024 5:45 am
Insider Sale: CFO Jane Henderson Sells 6,000 Shares of Apogee Therapeutics Inc (APGE) - Aug 24th, 2024 5:30 am
Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG990, its Novel Half-Life Extended OX40L Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases - Aug 19th, 2024 11:00 am
Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2024 Financial Results - Aug 12th, 2024 10:30 am